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We are intrigued by the recent case report of two 
stepsisters who were treated with natalizumab for 
multiple sclerosis (MS) and developed progressive 
multifocal leukoencephalopathy (PML) 5 months 
apart.1 This is reminiscent of our own report about the 
co-occurrence of PML in two MS patients who were 
members of a “natalizumab-infusion group”.2
The two stepsisters described by Bacchetta et al.1 had 
close contact before and after the first patient devel-
oped PML. After PML was diagnosed in the first 
patient, her stepsister insisted that her neurologist 
ordered a magnetic resonance imaging (MRI) scan to 
reassure she had not PML. MRI showed a highly sug-
gestive clinically asymptomatic lesion in her cerebel-
lum, and PML was confirmed by CSF John Cunningham 
polyomavirus-polymerase chain reaction in the cere-
brospinal fluid (JCV-PCR). After natalizumab was 
discontinued, she developed symptomatic immune 
reconstitution inflammatory syndrome (IRIS).1
In striking parallel, after PML was diagnosed in the 
first patient of our “infusion group,” the second 
patient stopped natalizumab because of fear of PML. 
Six weeks later, she developed new brainstem symp-
toms caused by a PML lesion in her brainstem.2 
PML was confirmed by CSF JCV-PCR. Subsequently, 
the other members of the infusion group, who met 
monthly to receive natalizumab infusions in the 
same room at their neurologist’s infusion center, also 
discontinued natalizumab because they were con-
cerned about infection.2
In our PML cases, we had the chance to compare the 
mutated non-coding control regions (NCCR) of viral 
DNA. We found that the JCV NCCR was unique to 
each patient. This seemed to argue against the pos-
sibility of direct viral transmission between the 
patients. However, as we discussed in our paper, 
“there remains the remote possibility that an arche-
type-like strain of JCV spread by de novo infection 
from one patient to the other at an earlier time point 
and subsequently mutated independently in the two 
patients.”2 Alternatively, a shared pathogenic viral 
variant might have escaped detection by PCR.
In contrast to our report, no viral PCR sequences are 
available from the PML-affected stepsisters.1 The 
authors point out that between 2005 and 2016 there 
were only three cases of natalizumab-associated PML 
(including the two stepsisters) in a region of 
Switzerland encompassing 1.5 million inhabitants. A 
puzzling aspect of the Swiss report is that if PML 
indeed spread from patient to patient, there was appar-
ently only a short latency of a few months before the 
second stepsister developed PML.1
Viewed together, these observations1,2 renew concern 
that in rare instances, transmission of natalizumab-
associated PML might occur between immunocom-
promised patients who have close contact, as was the 
case with the Swiss stepsisters and with our “natali-
zumab infusion group.” Against this background, the 
advice that “pre-disposed patients (e.g. natalizumab-
treated patients, AIDS/immunosuppressed patients) 
should avoid direct contact with active PML patients”1 
makes a lot of sense.
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